An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy

NCT02538666 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

907

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Ipilimumab
OTHER: Placebo

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]